India’s Cheaper Weight-Loss Drugs Could Transform Global Obesity Treatment
India is on the verge of a major shift in the fight against obesity, as the patent for semaglutide – the key ingredient behind blockbuster drugs like Ozempic and Wegovy – expires in the country.
The development will allow Indian pharmaceutical companies to produce more affordable generic versions of the drug, potentially slashing treatment costs by more than half and significantly expanding access for millions of patients.
Semaglutide, originally developed by Novo Nordisk to treat diabetes, has gained global attention for its effectiveness in weight loss. It belongs to a class of drugs known as GLP-1 receptor agonists, which help regulate appetite and blood sugar levels by making users feel full for longer.
With the patent expiry, analysts expect a surge of competition. Reports suggest that as many as 50 generic versions could enter the Indian market within months – a common trend in the country’s highly competitive pharmaceutical industry.
This influx is expected to drive prices down significantly. Current monthly treatments, which can cost between 8,800 and 16,000 rupees, may drop to as low as 3,000 to 5,000 rupees, making the drugs far more accessible to the average patient.
India, often referred to as the “pharmacy of the world,” is already the largest supplier of generic medicines globally, accounting for about 20% of worldwide supply. The country produces tens of thousands of drug brands and exports medicines to over 200 countries, including major markets like the United States and the United Kingdom.
The potential impact of cheaper semaglutide extends beyond India. Experts believe it could reshape global obesity treatment by making effective weight-loss drugs available to a much wider population, particularly in developing regions.
The demand is already there. India has more than 77 million people living with Type 2 Diabetes and a rapidly growing population of overweight adults, driven by urban lifestyles and dietary habits.
Medical professionals say the drugs could become a powerful tool across multiple specialties – from cardiology to orthopaedics – helping patients lose weight before procedures and manage related health conditions.
However, experts are also urging caution.
Doctors warn that while semaglutide is effective, it is not without risks. Side effects can include nausea and digestive issues, while improper use could lead to more serious complications. There are also concerns about misuse, especially as prices fall and access increases.
Some patients, influenced by social media trends, expect rapid results without lifestyle changes. But experts stress that sustainable weight loss still depends on proper diet, exercise, and medical supervision.
Regulators in India have already stepped in, warning pharmaceutical companies against directly advertising such prescription drugs to consumers or making exaggerated claims about their effects.
There are also concerns about quality control. As more manufacturers enter the market, ensuring high production standards will be critical to maintaining trust in the drug’s safety and effectiveness.
Despite these challenges, the opportunity is massive. Lower-cost generics could dramatically expand access to treatment, not just in India but globally – potentially marking a turning point in how obesity and related conditions are managed worldwide.
